Скачать презентацию ABSORB Japan 3 -year Clinical and Angiographic Results Скачать презентацию ABSORB Japan 3 -year Clinical and Angiographic Results

af2530b58da8aced245fad9b58d9c805.ppt

  • Количество слайдов: 4

ABSORB Japan: 3 -year Clinical and Angiographic Results of a Randomized trial Evaluating the ABSORB Japan: 3 -year Clinical and Angiographic Results of a Randomized trial Evaluating the Absorb Bioresorbable Vascular Scaffold vs. Metallic Drug-eluting Stent in de novo Native Coronary Artery Lesions Ken Kozuma, Kengo Tanabe, Takeshi Kimura on behalf of the ABSORB Japan Investigators.

Study Design Patients with up to 2 de novo target lesions in separate native Study Design Patients with up to 2 de novo target lesions in separate native coronary arteries with a lesion length of ≤ 24 mm and a maximal diameter of ≥ 2. 5 mm to ≤ 3. 75 mm Randomized 2: 1 BVS N=266 Co. Cr-EES N=134 Tx. with single study device Diameter: 2. 5, 3. 0. 3. 5 mm Length: 8, 12, 18, 28 mm Post 1 M 6 M 12 M 13 M 2 Y 3 Y 4 Y 400 125 400 5 Y Y* Clinical FU Imaging Angiogram 400 OCT 1 125 at 3‐‐‐year: Clinical f/u 125 (Subrandomized) Angiographic f/u at 3‐‐‐year: 96. 5% • PI: Takeshi Kimura, Kyoto University 87. 3% QCA Corelab: Beth Israel Deaconess Medical Center, Inc. , Angiographic Core Lab, • • Boston Sponsor: Abbott Vascular

Clinical Summary Of Key Clinical and QCA Outcomes Co. Cr‐‐‐EES BVS P‐‐‐value (134 Pa. Clinical Summary Of Key Clinical and QCA Outcomes Co. Cr‐‐‐EES BVS P‐‐‐value (134 Pa. Dents) TLF 1. 6% (4) 1. 6% (2) 1. 00 ‐‐‐ Cardiac Death 0. 0% (0) 1. 00 ‐‐‐ Target Vessel MI 0. 4% (1) 0. 0% (0) 1. 00 1. 6% (4) BVS 0. 4% (1) (266 Pa. Dents) 1. 6% (2) Co. Cr‐‐‐EES 0. 0% (0) (134 Pa. Dents) TLF 8. 9% (23) 5. 5% (7) 0. 23 ‐‐‐ Cardiac Death 0. 4% (1) 0. 0% (0) 1. 00 ‐‐‐ Target Vessel MI 5. 4% (14) 3. 1% (4) 0. 31 ‐‐‐ ID‐‐‐TLR 7. 0% (18) 3. 9% (5) 0. 23 Definite/Probable ST 2‐‐‐ 3 Years (266 Pa. Dents) 3. 6% (9) 1. 6% (2) 0. 35 ‐‐‐ ID‐‐‐TLR Definite/Probable ST 0‐‐‐ 3 Years In-device MLD 1. 00 P‐‐‐value 1. 00 Pre Post 13 Months 3 Years BVS 0. 96± 0. 33 mm 2. 42 ± 0. 38 mm 2. 23 ± 0. 47 mm 2. 04 ± 0. 63 mm Co. Cr-EES 0. 99± 0. 36 mm 2. 64 ± 0. 40 mm 2. 48 ± 0. 53 mm 2. 40 ± 0. 56 mm 0. 42 <0. 0001 P-value

Relevance of the trial • • • The 2 -year results of Absorb III Relevance of the trial • • • The 2 -year results of Absorb III and Absorb Japan showed a relatively high incidence of TLF in Absorb compared to XIENCE. – Comparable safety and effectiveness was observed in ABSORB Japan between both study arms from 2 to 3 years, with low incremental TLF rates reported for BVS (1. 6%) and Co. Cr-EES (1. 7%) due to predominant to increases in ID-TLR. At 3 -years, the question of great interest among interventional cardiologists is whether the slope of the scaffold thrombosis curve will decrease after 2 years. – Compared to the prior year, only 1 VLST occurred between 2 and 3 years, on day 810 and in a BVS-treated lesion with visibly high restenosis. Few studies have demonstrated long-term clinical and serial angiographic outcomes of Absorb BVS in a randomized fashion both at 13 -month and 3 -year. The 3 -year angiographic appearance would similarly be unique as this time-point is around the time of full scaffold resorption. – Late lumen loss of BVS at 3 years was within clinically acceptable range (< 0. 4 mm), and consistently with that observed in ABSORB II and consistent with the low ID-TLR rates reported within 2 -3 years.